GO Capital Fund

LeddarTech develops advanced detection and ranging systems using infrared LEDs and algorithms. It offers off-the-shelf smart sensor modules for various applications such as traffic management, autonomous vehicles, smart homes, and agriculture. The company provides interconnected sensor solutions for infrastructure, pollution monitoring, mobility, and traffic management in cities.

LeddarTech develops advanced detection and ranging systems using infrared LEDs and algorithms. It offers off-the-shelf smart sensor modules for various applications such as traffic management, autonomous vehicles, smart homes, and agriculture. The company provides interconnected sensor solutions for infrastructure, pollution monitoring, mobility, and traffic management in cities.

Alethia Biotherapeutics, Inc. is a biotechnology company based in Montreal, Canada, founded in 2002. It specializes in the discovery and development of monoclonal antibody-based therapeutics aimed at treating various forms of cancer, particularly focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. The company's product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the effectiveness of DNA-damaging chemotherapy agents; sCLU, a glycoprotein linked to multiple malignancies; AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases; and AB-0440, a protein involved in osteoclast differentiation associated with bone loss. Alethia Biotherapeutics employs patented STAR discovery technology to develop therapeutics that address clinically relevant disease-specific targets, thereby aiding healthcare professionals in managing cancer and its complications.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing etripamil, a rapid-onset calcium channel blocker for cardiovascular conditions. The lead product is etripamil, administered as a nasal spray for self-treatment of episodes of paroxysmal supraventricular tachycardia, with ongoing Phase III studies in the United States and Canada. The company is also advancing development for other cardiovascular indications, including atrial fibrillation and angina, with a Phase II program for atrial fibrillation with rapid ventricular response. Founded in 2003, Milestone is headquartered in Montreal.

Alethia Biotherapeutics, Inc. is a biotechnology company based in Montreal, Canada, founded in 2002. It specializes in the discovery and development of monoclonal antibody-based therapeutics aimed at treating various forms of cancer, particularly focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. The company's product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the effectiveness of DNA-damaging chemotherapy agents; sCLU, a glycoprotein linked to multiple malignancies; AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases; and AB-0440, a protein involved in osteoclast differentiation associated with bone loss. Alethia Biotherapeutics employs patented STAR discovery technology to develop therapeutics that address clinically relevant disease-specific targets, thereby aiding healthcare professionals in managing cancer and its complications.

Leap Medical, Inc. engages in designing, developing, manufacturing, and marketing products that provide the earliest possible indicators of a patient's medical condition. The company is based in Montreal, Canada.

Alethia Biotherapeutics, Inc. is a biotechnology company based in Montreal, Canada, founded in 2002. It specializes in the discovery and development of monoclonal antibody-based therapeutics aimed at treating various forms of cancer, particularly focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and cancer-induced bone loss. The company's product portfolio includes Isogranulatimide, a G2 checkpoint inhibitor that enhances the effectiveness of DNA-damaging chemotherapy agents; sCLU, a glycoprotein linked to multiple malignancies; AB-0447, which targets a specific antigen prevalent in over eighty-five percent of ovarian cancer cases; and AB-0440, a protein involved in osteoclast differentiation associated with bone loss. Alethia Biotherapeutics employs patented STAR discovery technology to develop therapeutics that address clinically relevant disease-specific targets, thereby aiding healthcare professionals in managing cancer and its complications.